|
KMID : 0882420070720060577
|
|
Korean Journal of Medicine
2007 Volume.72 No. 6 p.577 ~ p.579
|
|
|
Combination chemotherapy with docetaxel and cisplatin as first-line treatment in advanced gastric cancer: is it a new effective chemotherapy?
|
|
Shin Dong-Bok
|
|
|
Abstract
|
|
|
|
Advanced gastric carcinoma is associated with a poor prognosis. Although a number of combination chemotherapy regimens , usually based on 5FU and cisplatin, have been tested in randomized studies, there is no globally accepted standard therapy. Docetaxel is active against advanced gastric carcinoma and some investigators report a response rate ranging from 18% to 24% with a single-agent docetaxel. Kim et al performed a phase II trial with docetaxel plus cisplatin(DC) in patients with untreated advanced gastric cancer, which resulted in a response rate(per protocol population) of 42.4% but a response rate for the intent-to-treatment analysis is only 33.3%. Granulocytopenia worse than grade 3 occurred only in 7.6% in spite of older patients being included. Non-hematologic toxicities were negligible. The lower rate of hematologic and non-hematologic toxicities over a number of other studies is considered as clinically irrelevant. I would like to remind Dr Kim coutiously that he has to adress these discrepancies.
|
|
|
KEYWORD
|
|
|
Advanced gastric cancer, Docetaxel, Cisplatin
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|